1 |
Le Louedec F, Puisset F, Chatelut E, Tod M. Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice. Clin Pharmacokinet 2023;62:55-66. [PMID: 36631685 DOI: 10.1007/s40262-022-01200-8] [Reference Citation Analysis]
|
2 |
Zazo H, Lagarejos E, Prado-velasco M, Sánchez-herrero S, Serna J, Rueda-ferreiro A, Martín-suárez A, Calvo MV, Pérez-blanco JS, Lanao JM. Physiologically-based pharmacokinetic modelling and dosing evaluation of gentamicin in neonates using PhysPK. Front Pharmacol 2022;13:977372. [DOI: 10.3389/fphar.2022.977372] [Reference Citation Analysis]
|
3 |
Aguiar Zdovc J, Vaupotič M, Marolt G, Knez L, Režonja Kukec R, Čufer T, Vovk T, Grabnar I. Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors. Cancer Chemother Pharmacol. [DOI: 10.1007/s00280-022-04465-9] [Reference Citation Analysis]
|
4 |
Shriyan B, Mehta P, Patil A, Jadhav S, Kumar S, Puri AS, Govalkar R, Krishnamurthy MN, Punatar S, Gokarn A, Khattry N, Gota V. Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia. Eur J Clin Pharmacol 2022. [PMID: 35652931 DOI: 10.1007/s00228-022-03345-8] [Reference Citation Analysis]
|